GlaxoSmithKline To Pay $20M SEC Fine Over China Bribery

By Martin O'Sullivan
September 30, 2016, 6:09 PM EDT

U.K. drugmaker GlaxoSmithKline PLC will pay $20 million to the U.S. Securities and Exchange Commission to settle claims that it violated the Foreign Corrupt Practices Act through a scheme to bribe...

Already a subscriber? Click here to view full article